Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1985 1
1986 5
1987 2
1989 1
1990 3
1991 2
1992 6
1993 3
1994 5
1995 8
1996 3
1997 3
1998 3
1999 2
2000 5
2001 13
2002 1
2003 3
2004 7
2005 7
2006 3
2007 3
2008 4
2009 3
2010 6
2011 5
2012 2
2013 8
2014 3
2015 10
2016 8
2017 3
2018 7
2019 2
2020 2
2023 3
2024 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

142 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean h nagata[Author] (1,901 results)?
Dexamethasone-sparing on days 2-4 with combined palonosetron, neurokinin-1 receptor antagonist, and olanzapine in cisplatin: a randomized phase III trial (SPARED Trial).
Minatogawa H, Izawa N, Shimomura K, Arioka H, Iihara H, Sugawara M, Morita H, Mochizuki A, Nawata S, Mishima K, Tsuboya A, Miyaji T, Honda K, Yokomizo A, Hashimoto N, Yanagihara T, Endo J, Kawaguchi T, Furuya N, Sone Y, Inada Y, Ohno Y, Katada C, Hida N, Akiyama K, Ichikura D, Konomatsu A, Ogura T, Yamaguchi T, Nakajima TE. Minatogawa H, et al. Among authors: nawata s. Br J Cancer. 2024 Feb;130(2):224-232. doi: 10.1038/s41416-023-02493-7. Epub 2023 Nov 16. Br J Cancer. 2024. PMID: 37973958 Free PMC article. Clinical Trial.
The primary endpoint was complete response (CR) during the delayed (24-120 h) phase. The non-inferiority margin was set at -15%. RESULTS: A total of 281 patients were enrolled, 278 of whom were randomly assigned to Arm D4 (n = 139) or Arm D1 (n = 139). ...
The primary endpoint was complete response (CR) during the delayed (24-120 h) phase. The non-inferiority margin was set at -15%. RESU …
A Randomized Controlled Trial of Betamethasone on Fatigue in Patients With Advanced Cancer.
Miyazaki K, Ikenaga M, Sato T, Ueshima K, Nawata S, Horimatsu T, Komori E, Kirishima T, Kawabata K, Kawamura T, Kasai H, Suzukamo Y, Matsuzaki K, Kuwabara Y, Nakayama T; PASQol Study Group. Miyazaki K, et al. Among authors: nawata s. J Pain Symptom Manage. 2024 May;67(5):393-401.e1. doi: 10.1016/j.jpainsymman.2024.01.037. Epub 2024 Feb 7. J Pain Symptom Manage. 2024. PMID: 38331232 Clinical Trial.
NAD(P)H oxidase activation: a potential target mechanism for diabetic vascular complications, progressive beta-cell dysfunction and metabolic syndrome.
Inoguchi T, Nawata H. Inoguchi T, et al. Among authors: nawata h. Curr Drug Targets. 2005 Jun;6(4):495-501. doi: 10.2174/1389450054021927. Curr Drug Targets. 2005. PMID: 16026268 Review.
High glucose level and free fatty acids stimulate de novo diacylglycerol (DAG)-PKC pathway and subsequently stimulate reactive oxygen species (ROS) production through a PKC-dependent activation of NAD(P)H oxidase. Increasing evidence has also shown that NAD(P)H oxid …
High glucose level and free fatty acids stimulate de novo diacylglycerol (DAG)-PKC pathway and subsequently stimulate reactive oxygen specie …
Protein kinase C-dependent increase in reactive oxygen species (ROS) production in vascular tissues of diabetes: role of vascular NAD(P)H oxidase.
Inoguchi T, Sonta T, Tsubouchi H, Etoh T, Kakimoto M, Sonoda N, Sato N, Sekiguchi N, Kobayashi K, Sumimoto H, Utsumi H, Nawata H. Inoguchi T, et al. Among authors: nawata h. J Am Soc Nephrol. 2003 Aug;14(8 Suppl 3):S227-32. doi: 10.1097/01.asn.0000077407.90309.65. J Am Soc Nephrol. 2003. PMID: 12874436 Review.
In addition, expression of NAD(P)H oxidase components were shown to be upregulated in vascular tissues and kidney from animal models of diabetes. ...Taken together, these findings strongly suggest that the PKC-dependent activation of NAD(P)H oxidase may be an essent …
In addition, expression of NAD(P)H oxidase components were shown to be upregulated in vascular tissues and kidney from animal models …
Gastrointestinal Bleeding Due to the Rupture of Splenic Artery Caused by Pancreatic Carcinoma: A Case Requiring Repeated Transcatheter Arterial Embolization in a Short Period of Time.
Aoki R, Kobayashi Y, Nawata S, Kamide H, Sekikawa Z, Utsunomiya D. Aoki R, et al. Among authors: nawata s. Interv Radiol (Higashimatsuyama). 2023 Jun 3;8(2):88-91. doi: 10.22575/interventionalradiology.2022-0034. eCollection 2023 Jul 1. Interv Radiol (Higashimatsuyama). 2023. PMID: 37485488 Free PMC article.
However, hematemesis with signs of shock recurred 13 h later, and angiography showed rebleeding from the origin of the splenic artery. The splenic artery was subsequently embolized using an NBCA and lipiodol mixture. ...
However, hematemesis with signs of shock recurred 13 h later, and angiography showed rebleeding from the origin of the splenic artery …
A possible target of antioxidative therapy for diabetic vascular complications-vascular NAD(P)H oxidase.
Inoguchi T, Tsubouchi H, Etoh T, Kakimoto M, Sonta T, Utsumi H, Sumimoto H, Yu HY, Sonoda N, Inuo M, Sato N, Sekiguchi N, Kobayashi K, Nawata H. Inoguchi T, et al. Among authors: nawata h. Curr Med Chem. 2003 Sep;10(17):1759-64. doi: 10.2174/0929867033457133. Curr Med Chem. 2003. PMID: 12871120 Review.
Among various possible mechanisms, attention have increasingly been paid to NAD(P)H oxidase as the most important source of ROS production in vascular cells. High glucose level stimulates ROS production through protein kinase C (PKC)-dependent activation of vascular NAD(P) …
Among various possible mechanisms, attention have increasingly been paid to NAD(P)H oxidase as the most important source of ROS produ …
Activation of proteases in cerulein-induced pancreatitis.
Yamaguchi H, Kimura T, Mimura K, Nawata H. Yamaguchi H, et al. Among authors: nawata h. Pancreas. 1989;4(5):565-71. doi: 10.1097/00006676-198910000-00007. Pancreas. 1989. PMID: 2478999
Acute pancreatitis was induced by two intraperitoneal injections of 40 micrograms/kg of body weight of cerulein at intervals of 1 h. After the first cerulein injection, the active trypsin and elastase contents in the pancreas tissues significantly increased, and reached th …
Acute pancreatitis was induced by two intraperitoneal injections of 40 micrograms/kg of body weight of cerulein at intervals of 1 h. …
Aromatase in bone cell: association with osteoporosis in postmenopausal women.
Nawata H, Tanaka S, Tanaka S, Takayanagi R, Sakai Y, Yanase T, Ikuyama S, Haji M. Nawata H, et al. J Steroid Biochem Mol Biol. 1995 Jun;53(1-6):165-74. doi: 10.1016/0960-0760(95)00031-t. J Steroid Biochem Mol Biol. 1995. PMID: 7626449 Review.
Osteoblast-like cells showed aromatase activity, and an apparent Km and the Vmax were 4.74 +/- 0.78 nM (mean +/- SD, n = 3) and 0.83 +/- 0.79 fmol/mg protein/h for HOS, and 4.6 +/- 2.9 nM and 279 +/- 299 fmol/mg protein/h (mean +/- SD, n = 19) for HO, respectively. …
Osteoblast-like cells showed aromatase activity, and an apparent Km and the Vmax were 4.74 +/- 0.78 nM (mean +/- SD, n = 3) and 0.83 +/- 0.7 …
Effects of dialysis on the pharmacokinetics of salazosulfapyridine.
Inami Y, Yamaji K, Sato M, Gohda T, Io H, Nawata M, Hamada C, Takasaki Y, Tomino Y. Inami Y, et al. Among authors: nawata m. Rheumatol Int. 2013 Feb;33(2):535-9. doi: 10.1007/s00296-011-2179-1. Epub 2011 Nov 12. Rheumatol Int. 2013. PMID: 22080212
We examined the pharmacokinetics of SASP and its metabolites in RA patient on hemodialysis. Hemodialysis was started 2 h after administration of SASP at a dose of 250 or 500 mg. Blood samples were took 8 times during the observation period. ...
We examined the pharmacokinetics of SASP and its metabolites in RA patient on hemodialysis. Hemodialysis was started 2 h after admini …
142 results